Cytrx Corp. (CYTR)

LadRx Corporation Announces OTCQB Ticker Change to LADX

CytRx Corporation Relaunches as LadRx Corporation

European Patent Office Awards CytRx Key Patent

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

CytRx Partners with Oncology Development Expert to Advance LADR Platform

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference

CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer

CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

CytRx to Present at Upcoming Virtual LD Micro Conference

CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders

CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022

CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor

CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor

CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C

3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021

These former penny stocks have followed the path of AMC stock this month

CytRx to Present at Upcoming Investor Conferences